The DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.
Thiazolidinediones: the Forgotten Diabetes Medications
Open accessAbstract
Purpose of Review: Thiazolidinediones (TZDs) are the only pharmacologic agents that specifically treat insulin resistance. The beneficial effects of TZDs on the cardiovascular risk factors associated with insulin resistance have been well documented. TZD use has been limited because of concern about safety issues and side effects. Recent Findings: Recent studies indicate that cardiovascular toxicity with rosiglitazone and increase in bladder cancer with pioglitazone are no longer significant issues. There are new data which show that pioglitazone treatment reduces myocardial infarctions and ischemic strokes. New data concerning TZD-mediated edema, congestive heart failure, and bone fractures improves the clinician’s ability to select patients that will have minimal significant side effects. Summary: Thiazolidinediones are now generic and less costly than pharmaceutical company–promoted therapies. Better understanding of the side effects coupled with clear benefits on the components of the insulin resistance syndrome should promote TZD use in treating patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, pioglitazone lowers myocardial infarctions (MI) and ischemic strokes, according to recent findings.”
From A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents. (2024) · cites this paper as [67]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are no pharmacologic treatments that particularly treat insulin resistance other than TZDs.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Macrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
Ford, E. S. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1769 · Cited by 1,718
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Research works printed but not linked: 2
- Lebovitz HE. In: Wass JAH, Stewart PM, editors. The metabolic syndrome chapter 13.36 in Oxford textbook of endocrinology and diabetes 2nd Edition. Oxford: OXFORD University Press; 2011.
- Gervois P, Fruchart J-C, Staels B. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab. 2007;3:145–55. · DOI
Cited by
Sorted by citations
Items 301–388 of 388
Santos-Enriquez, A. K., Dayrit, F. M., Jesus, A. J. D., & Rojas, N. R. L. (2026) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2026.1756081 · Cited by 1
Food as Medicine: Therapeutic Nutrition for Healing and Function in Diabetic Patients
Saha, D., Majumder, S., Sinha, N. K., Banerjee, P., & Maiti, R. (2026) · Springer eBooks · doi:10.1007/978-981-95-8946-3_10 · Cited by 1
Pourbaba, Y., Pourshaban, P., Hashemi, A., Garmabdari, A., Sheikholislam, Z., Bayat, L., Naderi, N., Mahboubi‐Rabbani, M., Rezaee, E., & Tabatabai, S. A. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103368 · Cited by 1
PPARγ-dependent transcriptional regulation of Vaspin expression in adipocytes
Aibara, D., & Matsusue, K. (2026) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbag073 · Cited by 1
吴学碧, Ma, Y., Yin, X., Liu, J., & Zhang, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1863710 · Cited by 1
Diabetes Mellitus type 2: Management and follow up in Primary Health Care Center
Alkinani, A. A., Alkhrizi, I. M., Alkathiri, S. H., Alzubaidi, H. L. A., Alghanmi, A. A., Alghanmi, A. M., Alnashri, I. A., & Alruwaili Amal Muhaysin, B. (2021) · Archives of Pharmacy Practice · doi:10.51847/mvmt9sdifp · Cited by 2
AVAILABLE TREATMENTS FOR TYPE 2 DIABETES: A REVIEW
Sudan, S. S., & Batra, B. (2020) · International Journal of Engineering Applied Sciences and Technology · doi:10.33564/ijeast.2020.v05i03.098 · Cited by 1
Discharge Planning for People with Inpatient Hyperglycaemia: A Review on Pharmacological Management
Gangopadhyay, K. K., Sahay, R. K., Gupta, S., Ayyar, V. S., Das, S., Bhattacharya, S., Bhandari, S., & Bhattacharyya, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230224123707 · Cited by 1
The Effect of Pharmaceutical Agents on Lymphedema
Shetye, R., Mulhern, K., Subramani, S., & Campione, E. (2023) · Rehabilitation Oncology · doi:10.1097/01.reo.0000000000000342 · Cited by 1
PPARs and Their Emerging Role in Vascular Biology, Inflammation and Atherosclerosis
Balda, J., Papafilippaki, A., Johnstone, M., & Plutzky, J. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_4 · Cited by 1
Diabetes Treatment and Prevention Using Herbal Medicine
Yusuf, B. O., Abdulsalam, R. A., & Sabiu, S. (2023) · Reference series in phytochemistry · doi:10.1007/978-3-031-21973-3_43-1 · Cited by 1
Kumar, D. A., Hameed, S., Kumar, M., & Singh, A. (2024) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2024.v84i03.022 · Cited by 1
Sharma, C., & Badyal, D. K. (2024) · National Journal of Pharmacology and Therapeutics · doi:10.4103/njpt.njpt_1_24 · Cited by 1
Fath, T., Theodorea, C. F., Idrus, E., Mashima, I., Suniarti, D. F., & Soekanto, S. A. (2024) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2024.101539 · Cited by 1
Varshosaz, J., Ahmadipour, S., & Dezhangfard, A. (2024) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_65_23 · Cited by 1
Diabetes mellitus: An overview
Sonia, T. A., & Sharma, C. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30272-5.00007-x · Cited by 1
Balani, P., Lopez, A. R., Nobleza, C. M. N., Siddiqui, M., Shah, P., & Khan, S. (2020) · Cureus · doi:10.7759/cureus.12372 · Cited by 1
Roles of PPARα and PPARγ As Regulator of Free Fatty Acids in Nonalcoholic SteatohepatitisPreprint
Vu, H. T., Nguyen, V. D., & Matsubara, T. (2023) · Preprints.org · doi:10.20944/preprints202304.0356.v1 · Cited by 1
Bailey, C. J., & Krentz, A. J. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch35 · Cited by 1
Antidiabetikumok új szerepben – újdonságok a Magyarországon elérhető SGLT-2-gátlóknál
Simonyi, G. (2020) · Diabetologia Hungarica · doi:10.24121/dh.2020.20
Deng, Y., Luo, H., Deng, Y., Yang, Y., Yao, X., Zhang, J., Su, Y., & He, B. (2021) · Research Square · doi:10.21203/rs.3.rs-509252/v1
Diabetesa gaixotasun inflamatorio gisa
Alquiza, A., Echeazarra, L., Gallego, M., & Casis, Ó. (2021) · EKAIA Euskal Herriko Unibertsitateko Zientzi eta Teknologi Aldizkaria · doi:10.1387/ekaia.22710
Systemic rosiglitazone administration leads to cementocytes apoptosis in wild type mice
da Silva, R. A. B., da Silva, L. A. B., de Oliveira, K. M. H., Lima, R. B., & Consolaro, A. G. (2021) · Scientia Plena · doi:10.14808/sci.plena.2021.076701
Schürmann, A., & Joost, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_48
Schürmann, A., & Joost, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-21573-6_48-1
Standard and innovative options in the treatment of insulin resistance
Metelski, J., Krauze-Kuc, K., Metelska, A., Sereda, D., & Nieścior, H. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.08.041
The Emerging Importance of Cellular Insulin Resistance in Diabetic Kidney Disease
Coward, R. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00272-8
Skolik, R. (2022) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3837
Drugs Causing Cystoid Macular Edema: Pathogenesis, Diagnosis, and Treatment
YILMAZ, M. (2022) · Güncel Retina Dergisi (Current Retina Journal) · doi:10.37783/crj-0339
Saputri, W. D., Lukiati, B., Susanto, H., Putra, W. E., Fadhilah, D. N., Fa’ida, S. B. R. N., Ariyani, F., & Faizah, A. N. (2023) · AIP conference proceedings · doi:10.1063/5.0111707
COVID-19 among Hospitalized Patients with Diabetes in Karachi: A Single Centre Study
Aijaz, W., Ahsan, T., Pal, B., Rani, B., Imran, P., & Qasim, S. F. (2023) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2023173158 · Cited by 1
Issues of insulin therapy for type 2 diabetes and ways to solve them
Katerenchuk, V. I., & Katerenchuk, A. V. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.3.2023.1277
Mannucci, E., & Scoccimarro, D. (2023) · Practical issues in geriatrics · doi:10.1007/978-3-031-28061-0_23
Hejazian, S. M., Vahed, S. Z., Haghighi, N. K., Niknafs, B., & Farnood, F. (2023) · Journal of Renal Injury Prevention · doi:10.34172/jrip.2023.32186
Liberitera, S., Solihah, I., & Sari, Y. E. (2023) · Jurnal Penelitian Sains · doi:10.56064/jps.v25i2.799 · Cited by 2
Carbohydrate intake and diabetic drugs: Understanding the dynamic interplay in diabetes managementPreprint
Mphasha, M. H., & Vagiri, R. V. (2023) · Research Square · doi:10.21203/rs.3.rs-3376214/v1
Embryonic adipose development and consequences in later life
Schulz, J. M., Tamayo, A., Moulin, C., Altilio, I., & Xu, X. (2023) · SCIREA journal of biology. · doi:10.54647/biology180324
HIPOGLICEMIANTES ORAIS: UMA ANÁLISE DE SEUS EFEITOS, INDICAÇÕES E CONTRAINDICAÇÕES
Domingos, G. F., Coimbra, Y. S., Ribeiro, B. P., Caldas, V. H. R., & Freitas, T. M. (2024) · Revista Foco · doi:10.54751/revistafoco.v17n4-041
Few promising medicinal plants as anti-diabetic agent
Hoque, M., Hossain, M. F., Tusher, S. T. I., Aktaruzzaman, M., & Hasan, A. (2024) · International Journal of Pharmacognosy and Life Science · doi:10.33545/27072827.2024.v5.i1b.113
Collaboration of alogliptin and pioglitazone: a double hit on the target
Салухов, В. В., Анатольевна, К. Е., & Ilyinskaya, Т. A. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-157
Ibeyaima, A., & Manna, P. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4835518
Hepatoprotective Role of Aqueous Extract of Kasni Seeds in Alloxan-Induced Diabetic Mice
Hamza, M., Mujhtaba, H. A., Aslam, A., Suhail, Z., Mehmood, K., & Salamat, A. (2024) · Journal of Health and Rehabilitation Research · doi:10.61919/jhrr.v4i3.1173
Mudaliar, S., Godani, N., & Sharma, S. (2025) · Current Analytical Chemistry · doi:10.2174/0115734110331672241216040932
Current methods of treatment of type 2 diabetes mellitus (literature review)
Mineeva, E. A., Zubareva, A. S., & Bontsevich, R. A. (2024) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-24012-08
Insulin Resistance in Type 1 Diabetes and Its Treatment Strategies
孙, 全. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153617
JULIET, A., & Veeraveedu, P. T. (2025) · Chromatographia · doi:10.1007/s10337-025-04404-9
Miscellaneous drug combinations in diabetes mellitus
Agarwal, S., Devi, M., Mani, D. N., & Gupta, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29129-6.00005-1
Antidiabetic flavonoids from plant sources
Nyandoro, S. S., Mbegeze, M. B., Stephano, F., & Munissi, J. J. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30086-8.00020-6
Mishra, A., Fatima, Z., Ved, A., Srivastava, S., & Yasir, M. (2025) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2025.00470
Zhang, Y., Xiao, S., Miao, H., Lu, C., Zhao, Q., Shao, Z., & Chen, T. (2025) · BioChem · doi:10.3390/biochem5030027
Molecular and cellular targets in the management of metabolic diseases and disorders: An overview
Cariño‐Cortés, R., Isabel, S.-C. M., Antonio, E.-D. J., Luis, J.-S., Fernández‐Martínez, E., & Fernanda, V.-C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00004-4
Innovative nanotechnological approaches to diabetes treatment: the role of metal oxide nanoparticles
Shaban, E. E., & El-Aziz, M. E. A. (2025) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2025.2566460
Sen, D. B., Baldha, K., Sen, A. K., Maheshwari, R. A., Zanwar, A. S., Raval, R. R., & Munde, M. K. (2025) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2025.00675
Chen, S., Yang, D., Jing, C., Chen, X., Jin, W., Lv, D., Liu, T., & Liu, Y. (2025) · Journal of Visualized Experiments · doi:10.3791/69500
Mu, L., Wang, Z., Ren, J., Xiong, X., Jin, Z., & Liu, X. (2022) · Figshare · doi:10.6084/m9.figshare.19181492
Zhao, H., Xing, C., Zhang, J., & He, B. (2021) · Figshare · doi:10.6084/m9.figshare.15253551
Mu, L., Wang, Z., Ren, J., Xiong, X., Jin, Z., & Liu, X. (2022) · Figshare · doi:10.6084/m9.figshare.19181501
Mu, L., Wang, Z., Ren, J., Xiong, X., Jin, Z., & Liu, X. (2022) · Figshare · doi:10.6084/m9.figshare.19181498
Jain, J. A., Doshi, B., Shete, A. P., & Ankad, B. S. (2025) · Indian Dermatology Online Journal · doi:10.4103/idoj.idoj_643_24
Sahu, A., Dwivedi, S., Awasthi, A. K., Srivastava, N., & Srivastava, K. (2026) · Springer eBooks · doi:10.1007/978-3-032-12320-6_9
Thiazolidinedione and reduced epilepsy risk: A population-based study using target trial emulation
Zhao, H., Zhuo, L., Zhang, B., Yin, Y., Sun, Y., Shen, P., Jiang, Z., & Zhan, S. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113184
Pathology and Vascular Biology of Atherosclerosis in Patients With Type 2 Diabetes
Plutzky, J., Virmani, R., & Schmidt, A. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00007-0
Foundations of Diabetes Technology
Joshi, D. M., Bhatt, H., & Patel, H. K. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898813635126010006
Insulin resistance and ischemic stroke
Пизова, Н. В., & Pizov, A. V. (2026) · Russian neurological Journal · doi:10.30629/2658-7947-2025-30-6-4-10
Mahammad, S. P., Muripiti, V., Chelimela, N., Rameshwar, N., & Satyanarayana, M. (2026) · Chemical Data Collections · doi:10.1016/j.cdc.2026.101237
Choi, Y. S., Jeon, J., Baik, M., Yoo, J., & Kim, J. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70341
Efficient C–H Functionalisation of Thiazole Derivatives Catalyzed by Pd–NHC Complexes
Evren, E., Gürbüz, N., & Özdemir, İ. (2026) · Topics in Catalysis · doi:10.1007/s11244-026-02300-6
Wind-Mark, K., Kunze, L. H., Willem, M., Palumbo, G. A., Giudici, C., Nuscher, B., Boening, G., Gildehaus, F. J., Lindner, S., Werner, R. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104632
Antibody-based therapies for type 2 diabetes mellitus (T2DM)
Ali, S., & Jamous, Y. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33590-7.00016-2
Robertson, T. I. (2026) · Computational and Theoretical Chemistry · doi:10.1016/j.comptc.2026.115950
Wang, X., Shen-tao, W., & Wang, B. (2026) · Current Radiopharmaceuticals · doi:10.1016/j.craph.2026.100073
Rodrigues, M. J., García‐Caparrós, P., Pereira, C. G., Magné, C., Hamed, K. B., de Mesquita, M. L., & Custódio, L. M. B. (2026) · Marine Drugs · doi:10.3390/md24080262
Oral Hypoglycemic Therapy in Metabolic Dysfunction-Associated Fatty Liver Disease
Karshina, O. O., Sabirov, I. S., & Mohammad, E. A. (2026) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-240-8-110-118
Rawat, S., Saraswat, J., Anand, A., Bhati, H., & Patel, R. (2026) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2026.129843
Kim, J., Jeon, J., Yoo, J., Baik, M., Heo, S., & Roh, J. W. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70385
Glucose-Responsive Nanomedicine in Diabetes Therapy: Emerging Advances and Clinical Prospects
Alsaei, A., Binrajab, A., Alsaei, S., Rahimi, F., Zarwi, A., Zarwi, H. N., AlAnsari, R., & Deen, G. R. (2026) · Journal of Functional Biomaterials · doi:10.3390/jfb17090424
Titus, C., Hoque, M. T., Bonin, R. P., & Bendayan, R. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106981
Himanshu, Verma, S., Yadav, S., Singh, A., Chauhan, J., Sameeksha, Sahu, K., & Mamgain, A. K. (2026) · Discover Endocrinology and Metabolism · doi:10.1007/s44417-026-00025-4
Liu, D., Xie, D., Che, X., Li, X., Xu, W., & Wu, G. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108456
Future GLP-1 receptor co-agonists and their cardiac effects
Neumann, J., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05908-3
Bhuyan, R., Medhi, N., Baruah, A. N., Choudhury, N., Thakuria, N., Choudhury, D., Sahariah, B. J., & Dasgupta, D. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100634
Moklesur, M., Islam, M. N., Simon, N. P., Islam, T., Naser, A. Z. M., Hafez, S., & Hasan, R. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104815
Rahamatolla, M., Belowar, S., Mondal, S. K. D., Datta, S. C., Mamun, M. A. A., & Rana, M. S. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100679
Yang, R., Zhang, S., Fu, Z., Yang, Y., Wang, Q., Zhou, Y., Li, J., Yang, R., Ning, S., Shi, Y., et al. (2026) · Medicinal Research Reviews · doi:10.1002/med.70117
Metadata
- Authors
- Lebovitz, H. E.
- Affiliations
- SUNY Downstate Health Sciences University (US)
- Corresponding author
- Lebovitz, Harold E.
- Venue
- Current Diabetes Reports
- Published
- 2019-11-27
- Volume
- 19
- Issue
- 12
- Pages
- 151-151
- ISSN
- 1534-4827 (ISSN-L)
- 1539-0829
- PMC
- PMC6881429
- OpenAlex
- W2990309084
- Cited by
- 388
- References
- 85
- Citations by year
- 2026: 45 · 2025: 62 · 2024: 75 · 2023: 68 · 2022: 65 · 2021: 57 · 2020: 16
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Current Diabetes Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- thiazolidinediones, insulin resistance, type 2 diabetes, rosiglitazone, pioglitazone, cardiovascular risk, myocardial infarction, ischemic stroke, bladder cancer, congestive heart failure, edema, bone fractures, drug safety, generic drugs
- MeSH terms
- Rosiglitazone, Pioglitazone, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin Resistance, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
